Drug intelligence / Profile preview

Bifidobacterium breve CGMCC No.11828

Development stage: Preclinical
Lead developer: Tinghu District People's Hospital
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium breve CGMCC No.11828 is a specific probiotic bacterial strain developed by The Peoples' Hospital of Tinghu District of Yancheng City for the treatment of ulcerative colitis. As a live biotherapeutic product, it is designed to restore microbial homeostasis in the gut, which is often disrupted in patients with inflammatory bowel disease. The strain works by enhancing the intestinal mucosal barrier and modulating the local immune system, specifically by suppressing the production of pro-inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-6 (IL-6), while potentially stimulating anti-inflammatory mediators like interleukin-10 (IL-10). This dual action helps to reduce colonic inflammation and promote mucosal healing.

Other names: Bifidobacterium breve strain CGMCC No.11828

Beyond the preview

Go deeper on Bifidobacterium breve CGMCC No.11828.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium breve CGMCC No.11828.

Explore the full profile